{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:45:49Z","timestamp":1791355549239,"version":"4.3.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072178"],"award-info":[{"award-number":["82072178"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272274"],"award-info":[{"award-number":["82272274"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Skin cutaneous melanoma (SKCM) is the most aggressive skin cancer, accounting for more than 75% mortality rate of skin-related cancers. As a newly identified programmed cell death, pyroptosis has been found to be closely associated with tumor progression. Nevertheless, the prognostic significance of pyroptosis in SKCM remains elusive.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 469 SKCM samples and 812 normal samples were obtained from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases. Firstly, differentially expressed pyroptosis-related genes (PRGs) between normal samples and SKCM samples were identified. Secondly, we established a prognostic model based on univariate Cox and LASSO Cox regression analyses, which was validated in the test cohort from GSE65904. Thirdly, a nomogram was used to predict the survival probability of SKCM patients. The R package \u201cpRRophetic\u201d was utilized to identify the drug sensitivity between the low- and high-risk groups. Tumor immune infiltration was evaluated using \u201cimmuneeconv\u201d R package. Finally, the function of GSDMD and SB525334 was explored in A375 and A2058 cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Based on univariate Cox and LASSO regression analyses, we established a prognostic model with identified eight PRGs (AIM2, CASP3, GSDMA, GSDMC, GSDMD, IL18, NLRP3, and NOD2), which was validated in the test cohort. SKCM patients were divided into low- and high-risk groups based on the median of risk score. Kaplan\u2013Meier survival analysis showed that high-risk patients had shorter overall survival than low-risk patients. Additionally, time-dependent ROC curves validated the accuracy of the risk model in predicting the prognosis of SKCM. More importantly, 4 small molecular compounds (SB525334, SR8278, Gemcitabine, AT13387) were identified, which might be potential drugs for patients in different risk groups. Finally, overexpression of GSDMD and SB525334 treatment inhibit the proliferation, migration, and invasion of SKCM cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In this study, we constructed a prognostic model based on PRGs and identified GSDMD as a potential therapeutic target, which provide new insights into SKCM treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-023-04513-9","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T11:02:09Z","timestamp":1699614129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["System analysis based on the pyroptosis-related genes identifes GSDMD as a novel therapy target for skin cutaneous melanoma"],"prefix":"10.1186","volume":"21","author":[{"given":"Shixin","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengdeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0076-038X","authenticated-orcid":false,"given":"Julin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,10]]},"reference":[{"issue":"1","key":"4513_CR1","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1186\/s12935-021-02409-6","volume":"21","author":"H Wang","year":"2021","unstructured":"Wang H, Xie X, Zhu J, Qi S, Xie J. Comprehensive analysis identifies IFI16 as a novel signature associated with overall survival and immune infiltration of skin cutaneous melanoma. Cancer Cell Int. 2021;21(1):694. https:\/\/doi.org\/10.1186\/s12935-021-02409-6.","journal-title":"Cancer Cell Int"},{"issue":"3","key":"4513_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4513_CR3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","volume":"80","author":"SM Swetter","year":"2019","unstructured":"Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, Gershenwald JE, Guild V, Grant-Kels JM, Halpern AC, Johnson TM, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208\u201350. https:\/\/doi.org\/10.1016\/j.jaad.2018.08.055.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"4513_CR4","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1038\/s41467-020-15546-9","volume":"11","author":"VW Rebecca","year":"2020","unstructured":"Rebecca VW, Somasundaram R, Herlyn M. Pre-clinical modeling of cutaneous melanoma. Nat Commun. 2020;11(1):2858. https:\/\/doi.org\/10.1038\/s41467-020-15546-9.","journal-title":"Nat Commun"},{"issue":"18","key":"4513_CR5","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1002\/cam4.4706","volume":"11","author":"S Ping","year":"2022","unstructured":"Ping S, Wang S, Zhao Y, He J, Li G, Li D, Wei Z, Chen J. Identification and validation of a ferroptosis-related gene signature for predicting survival in skin cutaneous melanoma. Cancer Med. 2022;11(18):3529\u201341. https:\/\/doi.org\/10.1002\/cam4.4706.","journal-title":"Cancer Med"},{"issue":"6","key":"4513_CR6","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/s41591-019-0476-5","volume":"25","author":"A Ribas","year":"2019","unstructured":"Ribas A, Lawrence D, Atkinson V, Agarwal S, Miller WH Jr, Carlino MS, Fisher R, Long GV, Hodi FS, Tsoi J, et al. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat Med. 2019;25(6):936\u201340. https:\/\/doi.org\/10.1038\/s41591-019-0476-5.","journal-title":"Nat Med"},{"key":"4513_CR7","doi-asserted-by":"publisher","first-page":"175883591983082","DOI":"10.1177\/1758835919830826","volume":"11","author":"MS Pelster","year":"2019","unstructured":"Pelster MS, Amaria RN. Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials. Ther Adv Med Oncol. 2019;11:1758835919830826. https:\/\/doi.org\/10.1177\/1758835919830826.","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"4513_CR8","doi-asserted-by":"publisher","first-page":"e1283462","DOI":"10.1080\/2162402X.2017.1283462","volume":"6","author":"E Simeone","year":"2017","unstructured":"Simeone E, Grimaldi AM, Festino L, Giannarelli D, Vanella V, Palla M, Curvietto M, Esposito A, Palmieri G, Mozzillo N, et al. Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. Oncoimmunology. 2017;6(3):e1283462. https:\/\/doi.org\/10.1080\/2162402X.2017.1283462.","journal-title":"Oncoimmunology"},{"issue":"4","key":"4513_CR9","doi-asserted-by":"publisher","first-page":"e1101207","DOI":"10.1080\/2162402X.2015.1101207","volume":"5","author":"JC Hassel","year":"2015","unstructured":"Hassel JC, Lee SB, Meiss F, Meier F, Dimitrakopoulou-Strauss A, J\u00e4ger D, Enk AH. Vemurafenib and ipilimumab: A promising combination? Results of a case series. Oncoimmunology. 2015;5(4):e1101207. https:\/\/doi.org\/10.1080\/2162402X.2015.1101207.","journal-title":"Oncoimmunology"},{"issue":"1","key":"4513_CR10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-021-00507-5","volume":"6","author":"P Yu","year":"2021","unstructured":"Yu P, Zhang X, Liu N, Tang L, Peng C, Chen X. Pyroptosis: mechanisms and diseases. Signal Transduct Target Ther. 2021;6(1):128. https:\/\/doi.org\/10.1038\/s41392-021-00507-5.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4513_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/CCO.0000000000000346","volume":"29","author":"V Petrilli","year":"2017","unstructured":"Petrilli V. The multifaceted roles of inflammasome proteins in cancer. Curr Opin Oncol. 2017;29(1):35\u201340. https:\/\/doi.org\/10.1097\/CCO.0000000000000346.","journal-title":"Curr Opin Oncol"},{"key":"4513_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev.immunol.021908.132715","volume":"27","author":"F Martinon","year":"2009","unstructured":"Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229\u201365. https:\/\/doi.org\/10.1146\/annurev.immunol.021908.132715.","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"4513_CR13","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/jid.2012.317","volume":"133","author":"W Liu","year":"2013","unstructured":"Liu W, Luo Y, Dunn JH, Norris DA, Dinarello CA, Fujita M. Dual role of apoptosis-associated speck-like protein containing a CARD (ASC) in tumorigenesis of human melanoma. J Invest Dermatol. 2013;133(2):518\u201327. https:\/\/doi.org\/10.1038\/jid.2012.317.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"4513_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13046-017-0553-x","volume":"36","author":"X Feng","year":"2017","unstructured":"Feng X, Luo Q, Zhang H, Wang H, Chen W, Meng G, Chen F. The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma. J Exp Clin Cancer Res. 2017;36(1):81. https:\/\/doi.org\/10.1186\/s13046-017-0553-x.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"4513_CR15","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/j.1349-7006.2012.02211.x","volume":"103","author":"Y Kondo","year":"2012","unstructured":"Kondo Y, Nagai K, Nakahata S, Saito Y, Ichikawa T, Suekane A, Taki T, Iwakawa R, Enari M, Taniwaki M, et al. Overexpression of the DNA sensor proteins, absent in melanoma 2 and interferon-inducible 16, contributes to tumorigenesis of oral squamous cell carcinoma with p53 inactivation. Cancer Sci. 2012;103(4):782\u201390. https:\/\/doi.org\/10.1111\/j.1349-7006.2012.02211.x.","journal-title":"Cancer Sci"},{"issue":"9","key":"4513_CR16","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41419-019-1883-8","volume":"10","author":"X Xia","year":"2019","unstructured":"Xia X, Wang X, Cheng Z, Qin W, Lei L, Jiang J, Hu J. The role of pyroptosis in cancer: pro-cancer or pro-\u201chost\u201d? Cell Death Dis. 2019;10(9):650. https:\/\/doi.org\/10.1038\/s41419-019-1883-8.","journal-title":"Cell Death Dis"},{"issue":"3","key":"4513_CR17","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jsb.2017.08.001","volume":"200","author":"B Wang","year":"2017","unstructured":"Wang B, Yin Q. AIM2 inflammasome activation and regulation: A structural perspective. J Struct Biol. 2017;200(3):279\u201382. https:\/\/doi.org\/10.1016\/j.jsb.2017.08.001.","journal-title":"J Struct Biol"},{"issue":"4","key":"4513_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41568-019-0123-y","volume":"19","author":"R Karki","year":"2019","unstructured":"Karki R, Kanneganti TD. Diverging inflammasome signals in tumorigenesis and potential targeting. Nat Rev Cancer. 2019;19(4):197\u2013214. https:\/\/doi.org\/10.1038\/s41568-019-0123-y.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4513_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.12296","volume":"265","author":"SM Man","year":"2015","unstructured":"Man SM, Kanneganti TD. Regulation of inflammasome activation. Immunol Rev. 2015;265(1):6\u201321. https:\/\/doi.org\/10.1111\/imr.12296.","journal-title":"Immunol Rev"},{"issue":"1","key":"4513_CR20","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248\u201362. https:\/\/doi.org\/10.1016\/j.celrep.2016.12.019.","journal-title":"Cell Rep"},{"issue":"7","key":"4513_CR21","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3390\/biomedicines9070839","volume":"9","author":"JY Heo","year":"2021","unstructured":"Heo JY, Do JY, Lho Y, Kim AY, Kim SW, Kang SH. TGF-\u03b21 receptor inhibitor sb525334 attenuates the epithelial to mesenchymal transition of peritoneal mesothelial cells via the TGF-\u03b21 signaling pathway. Biomedicines. 2021;9(7):839. https:\/\/doi.org\/10.3390\/biomedicines9070839.","journal-title":"Biomedicines"},{"key":"4513_CR22","doi-asserted-by":"publisher","first-page":"5230","DOI":"10.1038\/ncomms6230","volume":"5","author":"KA Milora","year":"2014","unstructured":"Milora KA, Miller SL, Sanmiguel JC, Jensen LE. Interleukin-1\u03b1 released from HSV-1-infected keratinocytes acts as a functional alarmin in the skin. Nat Commun. 2014;5:5230. https:\/\/doi.org\/10.1038\/ncomms6230.","journal-title":"Nat Commun"},{"issue":"1","key":"4513_CR23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41392-022-01046-3","volume":"7","author":"W Gao","year":"2022","unstructured":"Gao W, Wang X, Zhou Y, Wang X, Yu Y. Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy. Signal Transduct Target Ther. 2022;7(1):196. https:\/\/doi.org\/10.1038\/s41392-022-01046-3.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"4513_CR24","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/s41423-022-00905-x","volume":"19","author":"X Wei","year":"2022","unstructured":"Wei X, Xie F, Zhou X, Wu Y, Yan H, Liu T, Huang J, Wang F, Zhou F, Zhang L. Role of pyroptosis in inflammation and cancer. Cell Mol Immunol. 2022;19(9):971\u201392. https:\/\/doi.org\/10.1038\/s41423-022-00905-x.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"4513_CR25","doi-asserted-by":"publisher","first-page":"zcac033","DOI":"10.1093\/narcan\/zcac033","volume":"4","author":"R Mall","year":"2022","unstructured":"Mall R, Bynigeri RR, Karki R, Malireddi RKS, Sharma BR, Kanneganti TD. Pancancer transcriptomic profiling identifies key PANoptosis markers as therapeutic targets for oncology. NAR Cancer. 2022;4(4):zcac033. https:\/\/doi.org\/10.1093\/narcan\/zcac033.","journal-title":"NAR Cancer"},{"issue":"Pt A","key":"4513_CR26","doi-asserted-by":"publisher","first-page":"108270","DOI":"10.1016\/j.intimp.2021.108270","volume":"101","author":"S Qiu","year":"2021","unstructured":"Qiu S, Hu Y, Dong S. Pan-cancer analysis reveals the expression, genetic alteration and prognosis of pyroptosis key gene GSDMD. Int Immunopharmacol. 2021;101(Pt A):108270. https:\/\/doi.org\/10.1016\/j.intimp.2021.108270.","journal-title":"Int Immunopharmacol"},{"key":"4513_CR27","doi-asserted-by":"publisher","first-page":"109052","DOI":"10.1016\/j.cbi.2020.109052","volume":"323","author":"J Ruan","year":"2020","unstructured":"Ruan J, Wang S, Wang J. Mechanism and regulation of pyroptosis-mediated in cancer cell death. Chem Biol Interact. 2020;323:109052. https:\/\/doi.org\/10.1016\/j.cbi.2020.109052.","journal-title":"Chem Biol Interact"},{"issue":"3","key":"4513_CR28","doi-asserted-by":"publisher","first-page":"e90099","DOI":"10.1371\/journal.pone.0090099","volume":"9","author":"M Hergueta-Redondo","year":"2014","unstructured":"Hergueta-Redondo M, Sarri\u00f3 D, Molina-Crespo \u00c1, Megias D, Mota A, Rojo-Sebastian A, Garc\u00eda-Sanz P, Morales S, Abril S, Cano A, et al. Gasdermin-B promotes invasion and metastasis in breast cancer cells. PLoS ONE. 2014;9(3):e90099. https:\/\/doi.org\/10.1371\/journal.pone.0090099.","journal-title":"PLoS ONE"},{"issue":"3","key":"4513_CR29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/gcc.20636","volume":"48","author":"N Saeki","year":"2009","unstructured":"Saeki N, Usui T, Aoyagi K, Kim DH, Sato M, Mabuchi T, Yanagihara K, Ogawa K, Sakamoto H, Yoshida T, et al. Distinctive expression and function of four GSDM family genes (GSDMA-D) in normal and malignant upper gastrointestinal epithelium. Genes Chromosomes Cancer. 2009;48(3):261\u201371. https:\/\/doi.org\/10.1002\/gcc.20636.","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"4513_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1266\/ggs.85.75","volume":"85","author":"H Komiyama","year":"2010","unstructured":"Komiyama H, Aoki A, Tanaka S, Maekawa H, Kato Y, Wada R, Maekawa T, Tamura M, Shiroishi T. Alu-derived cis-element regulates tumorigenesis-dependent gastric expression of gasdermin B (GSDMB). Genes Genet Syst. 2010;85(1):75\u201383. https:\/\/doi.org\/10.1266\/ggs.85.75.","journal-title":"Genes Genet Syst"},{"issue":"4","key":"4513_CR31","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.3892\/or.2018.6634","volume":"40","author":"J Gao","year":"2018","unstructured":"Gao J, Qiu X, Xi G, Liu H, Zhang F, Lv T, Song Y. Downregulation of GSDMD attenuates tumor proliferation via the intrinsic mitochondrial apoptotic pathway and inhibition of EGFR\/Akt signaling and predicts a good prognosis in non-small cell lung cancer. Oncol Rep. 2018;40(4):1971\u201384. https:\/\/doi.org\/10.3892\/or.2018.6634.","journal-title":"Oncol Rep"},{"key":"4513_CR32","doi-asserted-by":"publisher","first-page":"3827999","DOI":"10.1155\/2023\/3827999","volume":"2023","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Han D, Duan H, Rao Q, Qian Y, Chen Q, Du X, Ni H, Wang S. Identification of pyroptosis-relevant signature in tumor immune microenvironment and prognosis in skin cutaneous melanoma using network analysis. Stem Cells Int. 2023;2023:3827999. https:\/\/doi.org\/10.1155\/2023\/3827999.","journal-title":"Stem Cells Int"},{"issue":"10","key":"4513_CR33","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1038\/cdd.2012.51","volume":"19","author":"R Pierini","year":"2012","unstructured":"Pierini R, Juruj C, Perret M, Jones CL, Mangeot P, Weiss DS, Henry T. AIM2\/ASC triggers caspase-8-dependent apoptosis in Francisella-infected caspase-1-deficient macrophages. Cell Death Differ. 2012;19(10):1709\u201321. https:\/\/doi.org\/10.1038\/cdd.2012.51.","journal-title":"Cell Death Differ"},{"issue":"24","key":"4513_CR34","doi-asserted-by":"publisher","first-page":"36185","DOI":"10.18632\/oncotarget.9154","volume":"7","author":"X Ma","year":"2016","unstructured":"Ma X, Guo P, Qiu Y, Mu K, Zhu L, Zhao W, Li T, Han L. Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway. Oncotarget. 2016;7(24):36185\u201397. https:\/\/doi.org\/10.18632\/oncotarget.9154.","journal-title":"Oncotarget"},{"issue":"7661","key":"4513_CR35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature22393","volume":"547","author":"Y Wang","year":"2017","unstructured":"Wang Y, Gao W, Shi X, Ding J, Liu W, He H, Wang K, Shao F. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017;547(7661):99\u2013103. https:\/\/doi.org\/10.1038\/nature22393.","journal-title":"Nature"},{"issue":"23","key":"4513_CR36","doi-asserted-by":"publisher","first-page":"6066","DOI":"10.1158\/1078-0432.CCR-18-1478","volume":"24","author":"H Lu","year":"2018","unstructured":"Lu H, Zhang S, Wu J, Chen M, Cai MC, Fu Y, Li W, Wang J, Zhao X, Yu Z, et al. Molecular targeted therapies elicit concurrent apoptotic and GSDME-dependent pyroptotic tumor cell death. Clin Cancer Res. 2018;24(23):6066\u201377. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1478.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4513_CR37","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"issue":"1","key":"4513_CR38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.canlet.2011.10.001","volume":"314","author":"JH Dunn","year":"2012","unstructured":"Dunn JH, Ellis LZ, Fujita M. Inflammasomes as molecular mediators of inflammation and cancer: potential role in melanoma. Cancer Lett. 2012;314(1):24\u201333. https:\/\/doi.org\/10.1016\/j.canlet.2011.10.001.","journal-title":"Cancer Lett"},{"issue":"4","key":"4513_CR39","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.tibs.2016.10.004","volume":"42","author":"J Shi","year":"2017","unstructured":"Shi J, Gao W, Shao F. Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci. 2017;42(4):245\u201354. https:\/\/doi.org\/10.1016\/j.tibs.2016.10.004.","journal-title":"Trends Biochem Sci"},{"issue":"8","key":"4513_CR40","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"KV Swanson","year":"2019","unstructured":"Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477\u201389. https:\/\/doi.org\/10.1038\/s41577-019-0165-0.","journal-title":"Nat Rev Immunol"},{"issue":"22","key":"4513_CR41","doi-asserted-by":"publisher","first-page":"5721","DOI":"10.1158\/0008-5472.CAN-12-0509","volume":"72","author":"MT Chow","year":"2012","unstructured":"Chow MT, Sceneay J, Paget C, Wong CS, Duret H, Tschopp J, M\u00f6ller A, Smyth MJ. NLRP3 suppresses NK cell-mediated responses to carcinogen-induced tumors and metastases. Cancer Res. 2012;72(22):5721\u201332. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-0509.","journal-title":"Cancer Res"},{"issue":"4","key":"4513_CR42","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3390\/cancers14040991","volume":"14","author":"F Scatozza","year":"2022","unstructured":"Scatozza F, Facchiano A. Expression of autoimmunity-related genes in melanoma. Cancers. 2022;14(4):991. https:\/\/doi.org\/10.3390\/cancers14040991.","journal-title":"Cancers"},{"issue":"9","key":"4513_CR43","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/j.jid.2023.03.1657","volume":"143","author":"LY Huang","year":"2023","unstructured":"Huang LY, Li ST, Lin SC, Kao CH, Hong CH, Lee CH, Yang LT. Gasdermin A is required for epidermal cornification during skin barrier regeneration and in an atopic dermatitis-like model. J Invest Dermatol. 2023;143(9):1735-1745.e11.","journal-title":"J Invest Dermatol"},{"issue":"10","key":"4513_CR44","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/s41556-020-0575-z","volume":"22","author":"J Hou","year":"2020","unstructured":"Hou J, Zhao R, Xia W, Chang CW, You Y, Hsu JM, Nie L, Chen Y, Wang YC, Liu C, et al. PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat Cell Biol. 2020;22(10):1264\u201375. https:\/\/doi.org\/10.1038\/s41556-020-0575-z.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"4513_CR45","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3892\/mmr.2019.10837","volume":"21","author":"J Wei","year":"2020","unstructured":"Wei J, Xu Z, Chen X, Wang X, Zeng S, Qian L, Yang X, Ou C, Lin W, Gong Z, et al. Overexpression of GSDMC is a prognostic factor for predicting a poor outcome in lung adenocarcinoma. Mol Med Rep. 2020;21(1):360\u201370. https:\/\/doi.org\/10.3892\/mmr.2019.10837.","journal-title":"Mol Med Rep"},{"issue":"1","key":"4513_CR46","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41418-018-0212-6","volume":"26","author":"D Frank","year":"2019","unstructured":"Frank D, Vince JE. Pyroptosis versus necroptosis: similarities, differences, and crosstalk. Cell Death Differ. 2019;26(1):99\u2013114. https:\/\/doi.org\/10.1038\/s41418-018-0212-6.","journal-title":"Cell Death Differ"},{"issue":"2","key":"4513_CR47","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/1751-2980.12576","volume":"19","author":"WJ Wang","year":"2018","unstructured":"Wang WJ, Chen D, Jiang MZ, Xu B, Li XW, Chu Y, Zhang YJ, Mao R, Liang J, Fan DM. Downregulation of gasdermin D promotes gastric cancer proliferation by regulating cell cycle-related proteins. J Dig Dis. 2018;19(2):74\u201383. https:\/\/doi.org\/10.1111\/1751-2980.12576.","journal-title":"J Dig Dis"},{"key":"4513_CR48","doi-asserted-by":"publisher","first-page":"105713","DOI":"10.1016\/j.intimp.2019.105713","volume":"74","author":"G Xi","year":"2019","unstructured":"Xi G, Gao J, Wan B, Zhan P, Xu W, Lv T, Song Y. GSDMD is required for effector CD8+ T cell responses to lung cancer cells. Int Immunopharmacol. 2019;74:105713. https:\/\/doi.org\/10.1016\/j.intimp.2019.105713.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"4513_CR49","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41420-022-00915-8","volume":"8","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Huang Z, Rui X, Wang Y, Wang Y, Zhou Y, Chen R, Chen Y, Wang Y, Li S, et al. GSDMD enhances cisplatin-induced apoptosis by promoting the phosphorylation of eIF2\u03b1 and activating the ER-stress response. Cell Death Discov. 2022;8(1):114. https:\/\/doi.org\/10.1038\/s41420-022-00915-8.","journal-title":"Cell Death Discov"},{"issue":"20","key":"4513_CR50","doi-asserted-by":"publisher","first-page":"18681","DOI":"10.1021\/acsami.9b01725","volume":"11","author":"F Gao","year":"2019","unstructured":"Gao F, Li W, Deng J, Kan J, Guo T, Wang B, Hao S. Recombinant human hair keratin nanoparticles accelerate dermal wound healing. ACS Appl Mater Interfaces. 2019;11(20):18681\u201390. https:\/\/doi.org\/10.1021\/acsami.9b01725.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"4513_CR51","doi-asserted-by":"publisher","first-page":"17997","DOI":"10.1038\/s41598-021-97603-x","volume":"11","author":"N Anabtawi","year":"2021","unstructured":"Anabtawi N, Cvammen W, Kemp MG. Pharmacological inhibition of cryptochrome and REV-ERB promotes DNA repair and cell cycle arrest in cisplatin-treated human cells. Sci Rep. 2021;11(1):17997. https:\/\/doi.org\/10.1038\/s41598-021-97603-x.","journal-title":"Sci Rep"},{"issue":"8","key":"4513_CR52","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.7150\/thno.82995","volume":"13","author":"L Guo","year":"2023","unstructured":"Guo L, Cen H, Weng J, He Y, Guo X, He D, Liu K, Duan S, Yang J, Zhang X, et al. PER2 integrates circadian disruption and pituitary tumorigenesis. Theranostics. 2023;13(8):2657\u201372. https:\/\/doi.org\/10.7150\/thno.82995.","journal-title":"Theranostics"},{"key":"4513_CR53","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.biomaterials.2018.10.022","volume":"189","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Bush X, Yan B, Chen JA. Gemcitabine nanoparticles promote antitumor immunity against melanoma. Biomaterials. 2019;189:48\u201359. https:\/\/doi.org\/10.1016\/j.biomaterials.2018.10.022.","journal-title":"Biomaterials"},{"issue":"12","key":"4513_CR54","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1158\/1535-7163.MCT-14-0452","volume":"13","author":"T Smyth","year":"2014","unstructured":"Smyth T, Paraiso KHT, Hearn K, Rodriguez-Lopez AM, Munck JM, Haarberg HE, Sondak VK, Thompson NT, Azab M, Lyons JF, et al. Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models. Mol Cancer Ther. 2014;13(12):2793\u2013804. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0452.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"4513_CR55","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12943-018-0889-7","volume":"17","author":"L Wang","year":"2018","unstructured":"Wang L, Tong X, Zhou Z, Wang S, Lei Z, Zhang T, Liu Z, Zeng Y, Li C, Zhao J, et al. Circular RNA hsa_circ_0008305 (circPTK2) inhibits TGF-\u03b2-induced epithelial-mesenchymal transition and metastasis by controlling TIF1\u03b3 in non-small cell lung cancer. Mol Cancer. 2018;17(1):140. https:\/\/doi.org\/10.1186\/s12943-018-0889-7.","journal-title":"Mol Cancer"},{"key":"4513_CR56","doi-asserted-by":"publisher","first-page":"108211","DOI":"10.1016\/j.pharmthera.2022.108211","volume":"240","author":"MT Bu","year":"2022","unstructured":"Bu MT, Chandrasekhar P, Ding L, Hugo W. The roles of TGF-\u03b2 and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors. Pharmacol Ther. 2022;240:108211. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108211.","journal-title":"Pharmacol Ther"},{"key":"4513_CR57","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jconrel.2021.06.012","volume":"336","author":"Y Li","year":"2021","unstructured":"Li Y, Hu Q, Li W, Liu S, Li K, Li X, Du J, Yu Z, Wang C, Zhang C. Simultaneous blockage of contextual TGF-\u03b2 by cyto-pharmaceuticals to suppress breast cancer metastasis. J Control Release. 2021;336:40\u201353. https:\/\/doi.org\/10.1016\/j.jconrel.2021.06.012.","journal-title":"J Control Release"},{"issue":"10","key":"4513_CR58","doi-asserted-by":"publisher","first-page":"e2105240","DOI":"10.1002\/advs.202105240","volume":"9","author":"H Peng","year":"2022","unstructured":"Peng H, Shen J, Long X, Zhou X, Zhang J, Xu X, Huang T, Xu H, Sun S, Li C, et al. Local release of TGF-\u03b2 Inhibitor modulates tumor-associated neutrophils and enhances pancreatic cancer response to combined irreversible electroporation and immunotherapy. Adv Sci. 2022;9(10):e2105240. https:\/\/doi.org\/10.1002\/advs.202105240.","journal-title":"Adv Sci"},{"issue":"3","key":"4513_CR59","doi-asserted-by":"publisher","first-page":"e0230230","DOI":"10.1371\/journal.pone.0230230","volume":"15","author":"H Wen","year":"2020","unstructured":"Wen H, Qian M, He J, Li M, Yu Q, Leng Z. Inhibiting of self-renewal, migration and invasion of ovarian cancer stem cells by blocking TGF-\u03b2 pathway. PLoS ONE. 2020;15(3):e0230230. https:\/\/doi.org\/10.1371\/journal.pone.0230230.","journal-title":"PLoS ONE"},{"issue":"8","key":"4513_CR60","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14(8):463\u201382. https:\/\/doi.org\/10.1038\/nrclinonc.2017.43.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7910","key":"4513_CR61","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41586-022-04682-5","volume":"605","author":"G Oliveira","year":"2022","unstructured":"Oliveira G, Stromhaug K, Cieri N, Iorgulescu JB, Klaeger S, Wolff JO, Rachimi S, Chea V, Krause K, Freeman SS, et al. Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. Nature. 2022;605(7910):532\u20138. https:\/\/doi.org\/10.1038\/s41586-022-04682-5.","journal-title":"Nature"},{"issue":"3","key":"4513_CR62","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.cell.2019.02.005","volume":"177","author":"M Binnewies","year":"2019","unstructured":"Binnewies M, Mujal AM, Pollack JL, Combes AJ, Hardison EA, Barry KC, Tsui J, Ruhland MK, Kersten K, Abushawish MA, et al. Unleashing type-2 dendritic cells to drive protective antitumor CD4+ T cell immunity. Cell. 2019;177(3):556-571.e16. https:\/\/doi.org\/10.1016\/j.cell.2019.02.005.","journal-title":"Cell"},{"issue":"3","key":"4513_CR63","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/CMR.0000000000000352","volume":"27","author":"M Falleni","year":"2017","unstructured":"Falleni M, Savi F, Tosi D, Agape E, Cerri A, Moneghini L, Bulfamante GP. M1 and M2 macrophages\u2019 clinicopathological significance in cutaneous melanoma. Melanoma Res. 2017;27(3):200\u201310. https:\/\/doi.org\/10.1097\/CMR.0000000000000352.","journal-title":"Melanoma Res"},{"issue":"1","key":"4513_CR64","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030.","journal-title":"N Engl J Med"},{"issue":"21","key":"4513_CR65","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1414428.","journal-title":"N Engl J Med"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04513-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04513-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04513-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T11:04:13Z","timestamp":1699614253000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04513-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4513"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04513-9","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,10]]},"assertion":[{"value":"5 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was conducted in accordance with the Helsinki Declaration and received approval from the Ethics Committee Board of the First Affiliated Hospital of Sun Yat\u2010Sen University (IIT-2022-474). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"801"}}